Total Payments
$1,922
2024 Payments
$779.89
Companies
26
Transactions
77
Medicare Patients
676
Medicare Billing
$106,635
Payment Breakdown by Category
Food & Beverage$1,542 (80.2%)
Education$379.65 (19.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,542 | 71 | 80.2% |
| Education | $379.65 | 6 | 19.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $246.35 | 6 | $0 (2024) |
| Astellas Pharma US Inc | $220.87 | 5 | $0 (2024) |
| Genentech USA, Inc. | $178.29 | 6 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $173.82 | 9 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $154.26 | 7 | $0 (2024) |
| PFIZER INC. | $142.40 | 9 | $0 (2024) |
| Janssen Biotech, Inc. | $127.95 | 6 | $0 (2024) |
| Eisai Inc. | $100.96 | 5 | $0 (2024) |
| Aveo Pharmaceuticals, Inc. | $99.00 | 1 | $0 (2024) |
| ARRAY BIOPHARMA INC | $51.61 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $779.89 | 27 | AstraZeneca Pharmaceuticals LP ($173.10) |
| 2023 | $293.29 | 8 | Astellas Pharma US Inc ($156.99) |
| 2022 | $294.66 | 13 | Janssen Biotech, Inc. ($56.23) |
| 2020 | $24.33 | 1 | Genentech USA, Inc. ($24.33) |
| 2018 | $511.85 | 27 | Genentech USA, Inc. ($153.96) |
| 2017 | $17.50 | 1 | Merck Sharp & Dohme Corporation ($17.50) |
All Payment Transactions
77 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.56 | General |
| Category: Oncology | ||||||
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $120.09 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $31.25 | General |
| Category: Oncology | ||||||
| 10/04/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: DESMOID TUMORS | ||||||
| 09/09/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: Oncology | ||||||
| 08/02/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $24.77 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $23.71 | General |
| Category: Oncology | ||||||
| 07/22/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug), Fabhalta | Food and Beverage | In-kind items and services | $34.24 | General |
| Category: Oncology | ||||||
| 07/16/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Oncology | ||||||
| 06/25/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $23.06 | General |
| Category: Oncology / Rare Diseases | ||||||
| 06/07/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.79 | General |
| Category: Oncology | ||||||
| 06/04/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $27.53 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: Oncology | ||||||
| 05/17/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: Oncology | ||||||
| 05/10/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: Oncology | ||||||
| 05/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.22 | General |
| 05/03/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: Oncology | ||||||
| 04/26/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $28.36 | General |
| Category: ONCOLOGY | ||||||
| 04/01/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: Oncology | ||||||
| 03/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.88 | General |
| 03/18/2024 | PFIZER INC. | IBRANCE (Drug), XTANDI, ORGOVYX | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $27.33 | General |
| Category: Oncology | ||||||
| 03/12/2024 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $22.68 | General |
| Category: Oncology | ||||||
| 03/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: Oncology | ||||||
| 02/08/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 203 | 380 | $94,243 | $42,624 |
| 2022 | 4 | 223 | 417 | $105,614 | $31,781 |
| 2021 | 3 | 155 | 235 | $59,986 | $23,128 |
| 2020 | 4 | 95 | 113 | $29,313 | $9,102 |
Total Patients
676
Total Services
1,145
Medicare Billing
$106,635
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 58 | 172 | $34,075 | $18,254 | 53.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $14,517 | $7,777 | 53.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 45 | $12,451 | $6,670 | 53.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 47 | 81 | $18,873 | $5,577 | 29.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 15 | 22 | $6,864 | $2,191 | 31.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 17 | 17 | $7,463 | $2,154 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 112 | 288 | $62,784 | $18,676 | 29.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 63 | 63 | $25,830 | $7,845 | 30.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 34 | 50 | $14,600 | $4,679 | 32.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 14 | 16 | $2,400 | $580.71 | 24.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 84 | 137 | $29,181 | $10,805 | 37.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 46 | 73 | $20,805 | $8,613 | 41.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 25 | 25 | $10,000 | $3,711 | 37.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 52 | 65 | $13,715 | $4,108 | 30.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 20 | 25 | $7,150 | $2,232 | 31.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 12 | 12 | $4,884 | $1,623 | 33.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 11 | 11 | $3,564 | $1,139 | 32.0% |
About Dr. Cecilia Choi, MD
Dr. Cecilia Choi, MD is a Medical Oncology healthcare provider based in Makawao, Hawaii. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1558562371.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cecilia Choi, MD has received a total of $1,922 in payments from pharmaceutical and medical device companies, with $779.89 received in 2024. These payments were reported across 77 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($1,542).
As a Medicare-enrolled provider, Choi has provided services to 676 Medicare beneficiaries, totaling 1,145 services with total Medicare billing of $106,635. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology, Medical Oncology
- Location Makawao, HI
- Active Since 05/30/2007
- Last Updated 09/06/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1558562371
Products in Payments
- IMFINZI (Biological) $200.65
- OPDIVO (Biological) $121.05
- Perjeta (Biological) $103.50
- Lenvima (Drug) $100.96
- FOTIVDA (Drug) $99.00
- IBRANCE (Drug) $74.48
- Xtandi (Drug) $63.88
- HEMLIBRA (Biological) $49.37
- IMBRUVICA (Drug) $45.20
- JADENU (Drug) $44.36
- XALKORI (Drug) $42.07
- OPDUALAG (Drug) $37.00
- SCEMBLIX (Drug) $34.24
- Nubeqa (Drug) $31.25
- BOSULIF (Drug) $30.38
- QINLOCK (Drug) $29.25
- RYBREVANT (Drug) $28.21
- LIBTAYO (Biological) $27.53
- PLUVICTO (Drug) $26.32
- Kyprolis (Biological) $24.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.